Company Encyclopedia
View More
name
Radiopharm Theranostics
RADX.US
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc.
1.945 T
RADX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking149/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-105.17%E
    • Profit Margin-306.44%E
    • Gross Margin-148.63%E
  • Growth ScoreA
    • Revenue YoY525.41%A
    • Net Profit YoY21.72%B
    • Total Assets YoY17.44%A
    • Net Assets YoY53.32%A
  • Cash ScoreB
    • Cash Flow Margin-32.63%D
    • OCF YoY525.41%A
  • Operating ScoreD
    • Turnover0.16D
  • Debt ScoreC
    • Gearing Ratio50.43%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Radiopharm Theranostics Held General Meeting

    Radiopharm Theranostics Ltd. held a general meeting on December 3, 2025. Shareholders approved the ratification of the prior issue of First Tranche Placement Shares, the issue of Second Tranche Placement Shares, Placement Attaching Options, and SPP Attaching Options. All proposals were carried.

    Reuters·
    US
    RADX
    +4.68%
    Reuters·
    US
    RADX
    +4.68%

    Radiopharm Theranostics Highlights Key Investor Considerations at AGM

    Radiopharm Theranostics Limited presented key investor considerations at its AGM, emphasizing risks in clinical trials and regulatory approvals. The presentation advises seeking professional investment advice and notes legal restrictions on distribution, especially in the U.S. The latest analyst rating for AU:RAD is a Buy with a A$0.05 price target. The company, listed on NASDAQ and ASX, focuses on radiopharmaceutical products for diagnostics and therapeutics.

    Tip Ranks·
    US
    RADX
    +4.68%
    Tip Ranks·
    US
    RADX
    +4.68%

    Radiopharm Theranostics Appoints Bruce Goodwin as Director

    Radiopharm Theranostics Ltd. has appointed Bruce Goodwin as a new director, effective November 19, 2025. This announcement was made via EDGAR by the company and is for informational purposes only.

    Reuters·
    US
    RADX
    +4.68%
    Reuters·
    US
    RADX
    +4.68%

    Radiopharm Theranostics Wins HREC Approval to Begin Phase 1 Trial of RAD 402 in Prostate Cancer

    Radiopharm Theranostics Ltd. has received approval from the Bellberry Human Research Ethics Committee in Australia to start a Phase 1 clinical trial of RAD 402 for advanced prostate cancer. RAD 402 is a radiotherapeutic targeting prostate cancer cells. This marks a significant step in developing new treatments for prostate cancer.

    Reuters·
    US
    RADX
    +4.68%
    Reuters·
    US
    RADX
    +4.68%

    Radiopharm Theranostics Achieves 50% Enrollment in Phase 2b Trial for Brain Metastases Imaging

    Radiopharm Theranostics has achieved 50% enrollment in its Phase 2b trial for RAD 101 imaging in brain metastases. Early data shows significant tumor uptake, potentially leading to a global Phase 3 trial. The company aims to complete enrollment and share results by 2026, enhancing its oncology radiopharmaceuticals market position. Analysts rate the stock as a Buy with a A$0.05 price target.

    Tip Ranks·
    US
    RADX
    +4.68%
    Tip Ranks·
    US
    RADX
    +4.68%
    © 2025 Longbridge｜Disclaimer